{"nctId":"NCT01490580","briefTitle":"Premedication Trial for Tracheal Intubation of the NEOnate","startDateStruct":{"date":"2012-05","type":"ACTUAL"},"conditions":["Premedication","Endotracheal Intubation"],"count":173,"armGroups":[{"label":"Atropine + Propofol","type":"EXPERIMENTAL","interventionNames":["Drug: atropine+ propofol"]},{"label":"Atropine + atracurium + sufentanil","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: atropine + atracurium + sufentanil"]}],"interventions":[{"name":"atropine+ propofol","otherNames":[]},{"name":"atropine + atracurium + sufentanil","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Corrected age \\< 45 weeks of gestational age\n* Currently hospitalized in a neonatal intensive care unit\n* Requiring semi-urgent or elective intubation\n* Equipped with a reliable and permeable IV line\n* Parental consent\n\nExclusion Criteria:\n\n* Lack of parental consent\n* Parental refusal\n* Sedative or anesthetic treatment in the previous 24 hours\n* Hemodynamic compromise defined as mean blood pressure\\< corrected GA and/or refill time \\> 3 seconds\n* Upper airway malformation\n* Life-threatening situation requiring immediate intubation\n* Inclusion in another trial not permitting any other participation\n* Impossibility to establish venous access\n* Any contra-indication to any experimental drug","healthyVolunteers":false,"sex":"ALL","maximumAge":"28 Days","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Patients With Prolonged Desaturation","description":"Pulse oxymetry value measured by Masimo technology below 80% for 60 seconds or more.\n\nDuration of intubation is defined by the time between first laryngoscope insertion and last laryngoscope removal after successful intubation. Successful intubation is defined by clear bilateral breath sounds, increasing heart rate and saturation (if previously low) and appropriate flow curves on the ventilator.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null},{"groupId":"OG001","value":"53","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Intubation Attempts","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"47","spread":null}]},{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"23","spread":null}]},{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"11","spread":null}]},{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Intubation Procedure","description":"Although the initial definition of procedure duration in the registered protocol was the time between the first laryngoscope insertion and last laryngoscope removal after successful intubation, the variable collected in the clinical research form was defined as the time between first laryngoscope insertion and the fixation of the tube with tape.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.0","spread":null},{"groupId":"OG001","value":"3.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Heart Rate","description":"Heart rate recordings 1 minute before the first injection and at 3, 6, 9, 12, 15, 30, 45 and 60 minutes after the first injection","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","spread":"19.5"},{"groupId":"OG001","value":"11.5","spread":"19.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"25.2"},{"groupId":"OG001","value":"11.7","spread":"25.3"}]}]}]},{"type":"SECONDARY","title":"Short Term Neurological Outcome: Worsening of Head Ultrasound","description":"Worsening of head ultrasound scans in the 7 days after intubation from the preinclusion evaluation, defined as either a normal scan before inclusion and any grade intraventricular hemorrhage (IVH) afterwards, or as a preinclusion grade 1 or 2 IVH scan deteriorating to grade 3 or 4 IVH, according to Papile's classification; This analysis was not centralized but performed in each center according to its usual protocols.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients Surviving Without Ages and Stages Questionnaire Score Below Threshold at Age 2","description":"Survival without risk of neurodevelopmental delay. Risk of neurodevelopmental delay was defined as no Ages and Stages Questionnaires (ASQ) domain score below threshold (-2 SD) at 2 years of corrected age. The ASQ includes 30 items in 5 neurodevelopmental domains: communication abilities, gross motor skills, fine motor skills, problem solving abilities, and personal-social skills. For each domain, the score obtained by the sum of the items ranges from 0 to 60 and the overall maximum ASQ score is 300 points. For each domain, the score can be categorized using established screening thresholds: an ASQ score \\<-2 SD below the mean suggests a risk of neurodevelopmental delay in that domai.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"45","spread":null}]}]}]},{"type":"SECONDARY","title":"Pulse Oxymetry","description":"Pulse oxymetry recordings 1 minute before the first injection and at 3, 6, 9, 12, 15, 30, 45 and 60 minutes after the first injection","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.0","spread":"20.1"},{"groupId":"OG001","value":"-12.0","spread":"20.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.7","spread":"22.3"},{"groupId":"OG001","value":"-15.9","spread":"22.2"}]}]}]},{"type":"SECONDARY","title":"Mean Blood Pressure","description":"Blood pressure recordings 1 minute before the first injection and at 3, 6, 9, 12, 15, 30, 45 and 60 minutes after the first injection","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.8","spread":"12.7"},{"groupId":"OG001","value":"0.2","spread":"12.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.1","spread":"9.3"},{"groupId":"OG001","value":"-3.3","spread":"9.4"}]}]}]},{"type":"SECONDARY","title":"Transcutaneous PCO2 (TcPCO2) Measurement","description":"TcPCO2 recordings 1 minute before the first injection and at 3, 6, 9, 12, 15, 30, 45 and 60 minutes after the first injection","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.0","spread":"14.4"},{"groupId":"OG001","value":"14.1","spread":"14.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.1","spread":"19.1"},{"groupId":"OG001","value":"16.2","spread":"19.3"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":9,"n":83},"commonTop":["Other","Hypertension","Hypotension, not treated","Bradycardia"]}}}